… Safety profile of vedolizumab … with the key words (vedolizumab OR MLN002) AND (inflammatory
bowel disease OR ulcerative colitis OR Crohn) AND (safety OR pregnan* OR infection …

… Vedolizumab efficacy and safety in moderate-to-severely active ulcerative colitis (UC) and
Crohn’s disease (… Clinical guidelines recommend vedolizumab for UC not previously treated …

… Vedolizumab discontinuation due to AEs occurred in 15% (UC) and 17% (CD) of patients.
There … The safety profile of vedolizumab remains favourable with no unexpected or new safety …

Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn’s disease (CD) or ulcerative colitis (UC). We investigated …

… the efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease. …
The purpose of this study was to assess the efficacy and safety of vedolizumab induction and …

… on efficacy and of vedolizumab in patients with inflammatory bowel disease (OBSERV-IBD) …
Here, we report the effectiveness and safety of vedolizumab maintenance therapy (at week …

… . Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in
adults with inflammatory bowel disease: additional results from GEMINI 1 and 2. Inflamm …

… of vedolizumab in patients with inflammatory bowel disease ( IBD ). … vedolizumab were
included. Effectiveness was defined based on Harvey‐Bradshaw index ( HBI ) in Crohn's disease …

… Vedolizumab [VDZ] is a monoclonal … Crohn’s disease [CD] and ulcerative colitis [UC] in
2014 led to a major expansion of the therapeutic armamentarium for inflammatory bowel disease, …

… bowel diseases (IBD), both in patients with Crohn's disease (CD) and ulcerative colitis (UC), …
Vedolizumab (VDZ) is a fully human immunoglobulin G1 monoclonal antibody selective for …